Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease
Part of paid clinical trials in Duarte, California.
- Sponsor
- City of Hope Medical Center
- Study ID
- NCT03279094
- Phase
- PHASE1
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 1 Year - 30 Years
- Healthy Volunteers
- Not accepted
Interventions
- Hematopoietic stem cell transplantation — BIOLOGICALHaploidentical stem cell transplantation with pre-transplant immunosuppressive therapy
Study Details
This is a study to evaluate the safety and toxicity of a treatment regimen consisting of 2 cycles of pre-transplant immunosuppressive therapy followed by myeloablative preparative regimen and allogeneic hematopoietic stem cell transplantation from a haploidentical donor in patients with sickle cell disease. The overall goal of this study is to expand the donor pool for hematopoietic stem cell transplantation in sickle cell disease using haploidentical donors, and to develop a non-toxic, myeloablative regimen, with the goal of achieving a consistent donor chimerism utilizing pre-transplant immunosuppressive therapy.
Key Dates
- Start date
- Feb 2, 2018
- Status verified
- May 2026
- Primary completion
- Jan 25, 2027
- Completion
- Jan 25, 2027
Study Design
- Enrollment
- 11 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Haploidentical stem cell transplantation
Primary Outcome Measure
Rate of unacceptable adverse events that are defined as any of the following events that occur from start of pre-transplant immunosuppressive therapy to the first 100 days post HCT: [ Time Frame: 190 days ]
Central Contacts
- Anna B. Pawlowska, MD626-218-8442
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope Medical Center | Duarte | California | 91010 | Anna B. Pawlowska, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Duarte, CA
Related Studies
- Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell DiseasePHASE2 · Recruiting · New York Medical College · Los Angeles, California
- A Long-term Follow-up Study in Participants Who Received CTX001PHASE3 · Enrolling By Invitation · Vertex Pharmaceuticals Incorporated · Palo Alto, California
- ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic DisordersRecruiting · American Thrombosis and Hemostasis Network · Phoenix, Arizona
- The BENeFiTS Trial in Beta Thalassemia IntermediaPHASE1/PHASE2 · Enrolling By Invitation · Phoenicia BioScience · Oakland, California